GSK Bio
NEWS
Ligand Pharmaceuticals is licensing LGD-6972, a glucagon receptor antagonist (GRA), to Roivant Sciences for $20 million.
Dynavax announced it has secured a $175 million non-dilutive term loan agreement to commercialize Heplisav-B.
If you had a crystal ball, you probably would have invested in Berkshire Hathaway in 1964, or Apple in the 1980s.
Since Emma Walmsley took over leadership at Glaxo, expectations have been both high and hypercritical.
Bexsero is the first vaccine in the world to receive the designation twice.
Companies including Sanofi, J&J, Nestle have dropped out.
Now insiders say J&J has decided it is no longer interested.
KaNDy Therapeutics is a clinical-stage company that is focused on female sex-hormone related conditions.
Narasimhan takes over the role of CEO in February as current CEO Joe Jimenez retires.
JOBS
IN THE PRESS